One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2021-146503
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 14 |
Affiliation: The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Harvard University, Hospital Universitari i Politècnic La Fe, Moffitt Cancer Center, Centre Antoine Lacassagne, University of California, Irvine, Istituto Oncologico Romagnolo, Fred Hutch Cancer Center, MD Anderson Cancer Center Madrid, Duke University, University Hospital Münster, Hôpital Saint-Louis, Université Paris Cité, Beth Israel Deaconess Medical Center, European Institute of Oncology, Cornell University, New York Hospital Queens, Presbyterian Hospital, NewYork–Presbyterian Hospital, ImmunoGen (United States), Hospices Civils de Lyon, Istituto di Ematologia di Bologna, Northwestern University, City of Hope, University of Michigan–Ann Arbor, Roswell Park Cancer Institute, City Of Hope National Medical Center, Instituto de Investigación Sanitaria La Fe, University Cancer Institute Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Cleveland Clinic, University of Eastern Piedmont Amadeo AvogadroSafety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
Sign-in/Register to access full text options 
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
